47 results on '"Imajo, Kento"'
Search Results
2. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
3. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
4. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
5. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD
6. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
7. Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort
8. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
9. New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis
10. Confounding factors in diagnostic performance of magnetic resonance elastography for staging liver fibrosis in patients with non-alcoholic fatty liver disease: an individual patient data meta-analysis
11. Diagnostic Accuracy of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Prospective Study
12. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
13. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study
14. Protective effect of SGL5213, a potent intestinal sodium–glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice
15. Utility of Ultrasound-Guided Attenuation Parameter for the Quantification of Steatosis with Reference to MRI-Based Proton Density Fat Fraction: A Multicenter, Prospective Study
16. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
17. Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice
18. Utility of magnetic resonance elastography in accurate identification of candidates for pharmacologic treatment of NASH related fibrosis: a prospective cohort study
19. Investigation of a composite imaging biomarker for identification of non-alcoholic steatohepatitis (NASH) patients in a Japanese population
20. Resolution of non-alcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial
21. 745 UTILITY OF MAGNETIC RESONANCE ELASTOGRAPHY IN ACCURATE DETECTION OF CANDIDATES FOR PHARMACOLOGIC TREATMENT OF NASH-RELATED FIBROSIS: A PROSPECTIVE COHORT STUDY
22. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
23. Efficacy of Lubiprostone in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Trial
24. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis
25. GS-01-Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, doubleblind, randomized, placebo-controlled, phase II study
26. SAT-306-Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease
27. SAT-307-A direct comparative study among magnetic resonance elastography, vibration controlled transient elastography and shear wave elastography in patients with non-alcoholic fatty liver disease
28. FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis
29. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants
30. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design
31. The High Prevalence and Predictors of Advance Fibrosis in Elderly Patients with Liver Biopsy Confirmed Non-Alcoholic Fatty Liver Disease (NAFLD): The Goasia Study
32. Characteristics of Fecal Microbiota in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Connection among Gut-Permeability, Endotoxin and NAFLD
33. Reply
34. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
35. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease
36. Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease
37. Sa1038 Genetic Analysis of Association With Pathogenesis and Progression of Nonalcoholic Fatty Liver Disease by Genome Wide Association Study (GWAS)
38. Sa1707 Analysis of Lipotoxicity in Liver Induced by Palmitate In Vivo
39. Mo1017 Clinical and Histologic Feature of Nonalcoholic Fatty Liver Disease With Normal ALT Values in a Large Retrospective Cohort in Japan
40. 611 Ifi6 Response Predicts Outcome of Treatment for Infection With Hepatitis C Virus With Novel Method for the Quantification of Interferon-Induced mRNA in Whole Blood
41. Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy
42. Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling
43. Tu1032 Relationship Between the Plasma Concentrations of Free Choline and Parameters of Adiposity and Histological Findings in Patients With Nonalcoholic Fatty Liver Disease. a Multicenter Study in Japan
44. Tu1044 Soluble CD14 are a Useful Hallmark of Liver Inflammation and Predictor for Progression of Fibrosis in NASH
45. Tu1037 Dipeptidyl Peptidase- 4 (Dpp-4) Inhibitor (Sitagliptin) as a Novel Treatment Agent for Nonalcoholic Fatty Liver Disease Patients With Type 2 Diabetes Mellitus
46. Acoustic radiation force-based shear stiffness and non-invasive panels of tests in Japanese patients with nonalcoholic fatty liver disease
47. S1841 Endothelial Nitric Oxide Synthase Changes the Fat Distribution in High-Fat Diet-Induced NAFLD Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.